Paper37709999
MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial.
Mitchell JM and 19 others. Nat Med, 2023. Cited by 304 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Papers, record 37709999. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37709999
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Stress Disorders, Post-Traumatic | Major topic |
| N-Methyl-3,4-methylenedioxyamphetamine | Major topic |
| Humans | |
| Treatment Outcome | |
| Combined Modality Therapy | |
| Double-Blind Method |
Source PubMed
Trials3
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT04077437 | A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP2) | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT06954025 | High-Intensity Inpatient MDMA-Assisted Psychotherapy for PTSD | Results | ClinicalTrials.gov | |
| NCT07737054 | Trauma-informed Psilocybin Assisted Psychotherapy (TiPAP) for PTSD | Background | ClinicalTrials.gov |
Comments and corrections2
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Erratum in | 39,375,459 | Author Correction: MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. | https://conductscience.org/library/papers/39375459 | PubMed |
| Comment in | 37,967,550 | Expectancy Effects Cannot Be Neglected in MDMA-Assisted Therapy Research. | https://conductscience.org/library/papers/37967550 | PubMed |
References38
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 11,119,398 | Cardiovascular effects of 3,4-methylenedioxymethamphetamine. A double-blind, placebo-controlled trial. | Ann Intern Med | 2000 | https://conductscience.org/library/papers/11119398 | PubMed |
| 2 | 32,063,234 | Psychological treatments for post-traumatic stress disorder in adults: a network meta-analysis. | Psychol Med | 2020 | https://conductscience.org/library/papers/32063234 | PubMed |
| 3 | 26,408,071 | The prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA): Controlled studies in humans and laboratory animals. | Neurosci Biobehav Rev | 2015 | https://conductscience.org/library/papers/26408071 | PubMed |
| 4 | 30,685,564 | Comparability of blinded remote and site-based assessments of response to adjunctive esketamine or placebo nasal spray in patients with treatment resistant depression. | J Psychiatr Res | 2019 | https://conductscience.org/library/papers/30685564 | PubMed |
| 5 | 36,352,123 | Serotonin-releasing agents with reduced off-target effects. | Mol Psychiatry | 2023 | https://conductscience.org/library/papers/36352123 | PubMed |
| 6 | 31,572,236 | Breakthrough for Trauma Treatment: Safety and Efficacy of MDMA-Assisted Psychotherapy Compared to Paroxetine and Sertraline. | Front Psychiatry | 2019 | https://conductscience.org/library/papers/31572236 | PubMed |
| 7 | 34,227,438 | Who is blind in psychedelic research? Letter to the editor regarding: blinding and expectancy confounds in psychedelic randomized controlled trials. | Expert Rev Clin Pharmacol | 2021 | https://conductscience.org/library/papers/34227438 | PubMed |
| 8 | 35,910,354 | Effects of 3,4-Methylenedioxymethamphetamine on Conditioned Fear Extinction and Retention in a Crossover Study in Healthy Subjects. | Front Pharmacol | 2022 | https://conductscience.org/library/papers/35910354 | PubMed |
| 9 | 28,493,729 | The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5): Development and initial psychometric evaluation in military veterans. | Psychol Assess | 2018 | https://conductscience.org/library/papers/28493729 | PubMed |
| 10 | 35,401,275 | Entactogens: How the Name for a Novel Class of Psychoactive Agents Originated. | Front Psychiatry | 2022 | https://conductscience.org/library/papers/35401275 | PubMed |
| 11 | 29,975,339 | Conceptualization, Assessment, and Treatment of Traumatic Stress in First Responders: A Review of Critical Issues. | Harv Rev Psychiatry | 2018 | https://conductscience.org/library/papers/29975339 | PubMed |
| 12 | 31,607,239 | Dissociative subtype of posttraumatic stress disorder in women in partial and residential levels of psychiatric care. | J Trauma Dissociation | 2020 | https://conductscience.org/library/papers/31607239 | PubMed |
| 13 | 31,065,731 | MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. | Psychopharmacology (Berl) | 2019 | https://conductscience.org/library/papers/31065731 | PubMed |
| 14 | 35,727,042 | MDMA-assisted therapy for posttraumatic stress disorder: A pooled analysis of ethnoracial differences in efficacy and safety from two Phase 2 open-label lead-in trials and a Phase 3 randomized, blinded placebo-controlled trial. | J Psychopharmacol | 2022 | https://conductscience.org/library/papers/35727042 | PubMed |
| 15 | 24,097,374 | MDMA enhances emotional empathy and prosocial behavior. | Soc Cogn Affect Neurosci | 2014 | https://conductscience.org/library/papers/24097374 | PubMed |
| 16 | 24,403,876 | MDMA (3,4-Methylenedioxymethamphetamine) Analogues as Tools to Characterize MDMA-Like Effects: An Approach to Understand Entactogen Pharmacology. | Curr Neuropharmacol | 2013 | https://conductscience.org/library/papers/24403876 | PubMed |
| 17 | 34,586,365 | Demographic and Health Behavior Factors Associated With Clinical Trial Invitation and Participation in the United States. | JAMA Netw Open | 2021 | https://conductscience.org/library/papers/34586365 | PubMed |
| 18 | 31,780,134 | Comorbidity in post-traumatic stress disorder: A population-based study from the two largest cities in Brazil. | J Affect Disord | 2020 | https://conductscience.org/library/papers/31780134 | PubMed |
| 19 | 29,524,515 | MDMA-assisted psychotherapy for PTSD: Are memory reconsolidation and fear extinction underlying mechanisms? | Prog Neuropsychopharmacol Biol Psychiatry | 2018 | https://conductscience.org/library/papers/29524515 | PubMed |
| 20 | 22,346,334 | Pharmacotherapy for Post-traumatic Stress Disorder In Combat Veterans: Focus on Antidepressants and Atypical Antipsychotic Agents. | P T | 2012 | https://conductscience.org/library/papers/22346334 | PubMed |
Cited by213
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 304 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,974,518 | Psychedelics in neurosurgery: Potential utility in prevention, perioperative care, pain management, and neurorehabilitation. | Surg Neurol Int | 2026 | https://conductscience.org/library/papers/42974518 | PubMed |
| 42,972,049 | A multi-institutional investigation of psilocybin's effects on mouse behavior. | Nat Neurosci | 2026 | https://conductscience.org/library/papers/42972049 | PubMed |
| 42,957,826 | Evolutionary neuropharmacology of serotonergic psychedelics: a cross-species perspective on mechanisms, consciousness, and therapeutic potential. | Mol Psychiatry | 2026 | https://conductscience.org/library/papers/42957826 | PubMed |
| 42,898,320 | Caution before canonisation: a clinical and implementation science perspective on psychedelics. | Front Psychiatry | 2026 | https://conductscience.org/library/papers/42898320 | PubMed |
| 42,891,831 | What goes up must comedown: prevalence rates, characteristics, and coping strategies concerning MDMA aftereffects. | Psychopharmacology (Berl) | 2026 | https://conductscience.org/library/papers/42891831 | PubMed |
| 42,875,076 | La psychothérapie assistée par des agents psychédéliques: Un paradigme émergent. | Can Fam Physician | 2026 | https://conductscience.org/library/papers/42875076 | PubMed |
| 42,875,067 | Psychedelic-assisted psychotherapy: Emerging paradigm. | Can Fam Physician | 2026 | https://conductscience.org/library/papers/42875067 | PubMed |
| 42,864,445 | Investigating molecular and hemodynamic effects of LSD in the human brain. | Nat Neurosci | 2026 | https://conductscience.org/library/papers/42864445 | PubMed |
| 42,860,436 | A living systematic review, meta-analysis, and open data resource of trials of MDMA-assisted therapy for PTSD. | Neuropsychopharmacology | 2026 | https://conductscience.org/library/papers/42860436 | PubMed |
| 42,823,699 | Post-traumatic stress disorder: outline and updated insights focusing on occupational factors. | J Occup Med Toxicol | 2026 | https://conductscience.org/library/papers/42823699 | PubMed |
| 42,812,288 | Lived experience as systems-relevant evidence in psychedelic public health. | Front Public Health | 2026 | https://conductscience.org/library/papers/42812288 | PubMed |
| 42,809,289 | Adverse Health Outcomes of Psilocybin, LSD, MDMA, Ibogaine, and 5-MeO-DMT. | JAMA Netw Open | 2026 | https://conductscience.org/library/papers/42809289 | PubMed |
| 42,809,102 | Moving beyond 5-HT2A: language models map neurotransmitter receptors to experiential semantics. | Psychopharmacology (Berl) | 2026 | https://conductscience.org/library/papers/42809102 | PubMed |
| 42,772,319 | Psychedelic-assisted therapy research for people with HIV. | Lancet HIV | 2026 | https://conductscience.org/library/papers/42772319 | PubMed |
| 42,761,569 | A national approach in a European context: Multidisciplinary and multiprofessional recommendations on the clinical use of psychedelic substances. | Neurosci Appl | 2026 | https://conductscience.org/library/papers/42761569 | PubMed |
| 42,735,067 | The Nova Protocol: a comprehensive multimodal longitudinal study among civilian survivors of a mass trauma event. | Eur J Psychotraumatol | 2026 | https://conductscience.org/library/papers/42735067 | PubMed |
| 42,687,955 | Medical and Psychiatric Consultation for Patients Considering State-Regulated Psilocybin Services: A Risk-Reduction Model and Two Illustrative Cases. | Res Sq | 2026 | https://conductscience.org/library/papers/42687955 | PubMed |
| 42,653,026 | Psychedelic Safety and Clinical Outcomes Across Exposure Patterns: A Structured Narrative Review. | Life (Basel) | 2026 | https://conductscience.org/library/papers/42653026 | PubMed |
| 42,577,141 | Medicine 4.0: the era of revolutionary access. | Front Med (Lausanne) | 2026 | https://conductscience.org/library/papers/42577141 | PubMed |
| 42,563,280 | Permissive and instructive causality: integrating biological and environmental factors in mental health. | Psychol Med | 2026 | https://conductscience.org/library/papers/42563280 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| AP2B1 | 163 | PubTator's text mining | https://conductscience.org/library/genes/163 |
Source NCBI Gene
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| MIDOMAFETAMINE | CHEMBL43048 | Results | 2 | https://conductscience.org/library/drugs/CHEMBL43048 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37709999
GET https://conductscience.org/api/papers/v1/37709999/references?page=2